C12N 2310/3533
Halogen
C12N2310/3533 (Halogen) appears on 262 US grants and 263 published applications in this corpus.
Search patents in C12N- Granted patents
- 262
- Published applications
- 263
- Assignees
- 103
- Inventors
- 508
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 15 | 0 |
| 1997 | 25 | 0 |
| 1998 | 17 | 0 |
| 1999 | 21 | 0 |
| 2000 | 17 | 0 |
| 2001 | 9 | 2 |
| 2002 | 15 | 5 |
| 2003 | 6 | 14 |
| 2004 | 3 | 7 |
| 2005 | 3 | 3 |
| 2006 | 4 | 3 |
| 2007 | 1 | 2 |
| 2008 | 0 | 2 |
| 2009 | 0 | 4 |
| 2010 | 3 | 5 |
| 2011 | 0 | 4 |
| 2012 | 4 | 2 |
| 2013 | 4 | 10 |
| 2014 | 3 | 6 |
| 2015 | 9 | 14 |
| 2016 | 9 | 20 |
| 2017 | 13 | 11 |
| 2018 | 9 | 19 |
| 2019 | 13 | 18 |
| 2020 | 6 | 13 |
| 2021 | 12 | 12 |
| 2022 | 10 | 14 |
| 2023 | 6 | 10 |
| 2024 | 8 | 18 |
| 2025 | 9 | 29 |
| 2026 | 4 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use8 Sep 2026US 12,729,377 B2Arrowhead Pharmaceuticals, Inc.
- Thrombus imaging aptamers and methods of using same4 Aug 2026US 12,697,401 B2Duke University
- RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use17 Feb 2026US 12,551,569 B2Arrowhead Pharmaceuticals, Inc.
- Binding and catalytic molecules built from expanded DNA6 Jan 2026US 12,516,317 B1
- RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use23 Dec 2025US 12,503,696 B2Arrowhead Pharmaceuticals, Inc.
- Oligonucleotides targeting gal3st124 Sep 2026US 2026/0286364 A1
- Oligonucleotides for htt-1a modulation10 Sep 2026US 2026/0265747 A1University of Massachusetts
- RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use27 Aug 2026US 2026/0248941 A1Arrowhead Pharmaceuticals, Inc.
- Oligonucleotide fragments and methods of making rnai agents using the same6 Aug 2026US 2026/0226459 A1Eli Lilly and Company
- RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use30 Jul 2026US 2026/0218190 A1Arrowhead Pharmaceuticals, Inc.
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997